Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Becton Dickinson and Co (BDX) vs Samsara Inc (IOT) Price & Performance

Becton Dickinson and CoTrade
Samsara IncTrade

Price performance (Past 24H)

Key statistics

Becton Dickinson and Co vs Samsara Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Samsara Inc trades at $40.16 (market cap $23.23B). The key difference: Becton Dickinson and Co is far larger — about 2.1× Samsara Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.

BDXIOT
Market Cap
$48.93B$23.23B
Sector
HealthTechnology
52-Week High
$185.39$45.22
52-Week Low
$138.62$24.25
Enterprise Value
$65.03B$22.49B
Dividend Yield
2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Samsara Inc

Samsara (IOT) trades at $40.88, up 6.96% in the last session, with a bullish technical signal from moving averages. The company reported revenue of $1.25B in 2025 but a net loss of $154.91M, though it has beaten EPS estimates for three consecutive quarters. Analyst sentiment is strongly positive, with 14 of 18 analysts rating it a Buy and a consensus price target of $44.50. Recent news highlights institutional buying and the company's focus on AI-driven growth.

The outlook is optimistic due to strong analyst support and consistent earnings beats, but risks include high valuation multiples and ongoing profitability challenges. Investors should weigh the growth potential in AI and connected operations against the current negative net income and elevated P/E ratio of 398.6.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT